Given our results showing extensive compensation between RAD51AP1 and RAD54L, we surmise that the simultaneous inactivation of both RAD51AP1 and RAD54L could be a viable strategy to treat cancer in the context of induced DNA damage. The gene discussed is RAD54L; the disease is cancer.